Winearls C G, Oliver D O, Pippard M J, Reid C, Downing M R, Cotes P M
Lancet. 1986 Nov 22;2(8517):1175-8. doi: 10.1016/s0140-6736(86)92192-6.
Ten patients with end-stage renal failure and anaemia (mean haemoglobin 6.1 g/dl, range 4.6-8.8 g/dl) on thrice-weekly haemodialysis were treated with human erythropoietin derived from recombinant DNA (rHuEPO). This was given as an intravenous bolus after each dialysis in rising doses within the range 3-192 IU/kg. All patients showed increases in reticulocyte numbers and haemoglobin concentration and after the first week of treatment none of the four previously transfusion-dependent patients needed further transfusions. In nine patients treated for 12 weeks haemoglobin rose to a mean of 10.3 g/dl, range 9.5 to 12.8 g/dl. Thereafter the dose of erythropoietin was adjusted to avoid a further rise in haemoglobin. During treatment one patient had an episode of hypertensive encephalopathy and two had clotting in their arteriovenous fistulas (complete in one). rHuEPO is an effective treatment for the anaemia of end-stage renal failure but longer-term observations are needed on the consequences of increasing the haematocrit.
对10例接受每周三次血液透析的终末期肾衰竭合并贫血患者（平均血红蛋白6.1g/dl，范围4.6 - 8.8g/dl）使用重组DNA来源的人促红细胞生成素（rHuEPO）进行治疗。每次透析后静脉推注给药，剂量在3 - 192IU/kg范围内递增。所有患者的网织红细胞数量和血红蛋白浓度均升高，治疗第一周后，之前4例依赖输血的患者均无需进一步输血。9例接受12周治疗的患者血红蛋白平均升至10.3g/dl，范围为9.5至12.8g/dl。此后调整促红细胞生成素剂量以避免血红蛋白进一步升高。治疗期间，1例患者发生高血压脑病，2例患者动静脉内瘘出现凝血（1例完全堵塞）。rHuEPO是终末期肾衰竭贫血的有效治疗方法，但对于提高血细胞比容的后果需要进行长期观察。
